Revelation's Financial Report Reveals Tight Cash Runway Revelation Biosciences ended 2024 with $6.5 million in cash, down from $12 million the previous year. The burn rate raises sustainability questions, though management believes funds will last into 2025. The firm focuses on its Gemini clinical trial, with topline data expected mid-year, potentially influencing future funding.56